FREE FEDEX 2-DAY SHIPPING OVER $200Same-Day Dispatch Before 1 PM ETThird-Party TestedBatch COAs Available
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE
Peptide Pilots
Log in
Comparative literatureGHRH analoguesEndocrinology

Growth Hormone Secretagogues Compared: Sermorelin, CJC-1295, Tesamorelin and Ipamorelin in the Literature

Four peptides are routinely grouped as 'growth hormone secretagogues', yet they act on two different receptors and rest on very different quality of evidence. Here is how the published literature separates them.

By Patrick Ergu, MSc, Molecular Pharmacology10 min read

This article summarises published scientific literature for laboratory professionals. It is not medical advice and does not describe human or veterinary use. All materials supplied by Peptide Pilots are for controlled laboratory research only.

Key takeaways

  • The commonly compared secretagogues act at two distinct receptors, so grouping them as one class obscures real mechanistic differences.
  • Half-life differences dominate practical comparisons between these peptides in the published literature.
  • Human data exists for only part of this group, and is narrower in scope than the preclinical literature suggests.

Two receptors, four peptides

The phrase 'growth hormone secretagogue' collapses two mechanistically distinct families into one shopping category. Sermorelin, CJC-1295 and tesamorelin are analogues of growth hormone-releasing hormone and act at the GHRH receptor on pituitary somatotrophs. Ipamorelin is a pentapeptide agonist of the growth hormone secretagogue receptor GHS-R1a, the receptor for ghrelin. The two receptors sit in different signalling contexts, and literature about one family does not transfer to the other.

  • Sermorelin — GHRH 1-29, the shortest fragment retaining full receptor activity; very short circulating half-life.
  • CJC-1295 without DAC (modified GRF 1-29) — GHRH 1-29 with substitutions that resist dipeptidyl peptidase-4 cleavage.
  • Tesamorelin — a trans-3-hexenoyl-modified GHRH 1-44 analogue with the largest published human trial programme of the four.
  • Ipamorelin — a selective GHS-R1a agonist reported in preclinical work to release growth hormone with limited effect on cortisol or prolactin.

Why half-life dominates the comparison

Native GHRH is cleaved rapidly at the Ala2 position by dipeptidyl peptidase-4, giving a plasma half-life measured in minutes. Almost every structural modification in this family exists to slow that cleavage: the substitutions in modified GRF 1-29, the acyl modification of tesamorelin, and, in the DAC-bearing version of CJC-1295, covalent albumin binding that extends exposure by orders of magnitude. Comparing two GHRH analogues without stating the exposure profile compares the wrong variable, because the pituitary response to pulsatile versus sustained receptor occupancy is not the same phenomenon.

This is also where the evidence base diverges most sharply. Tesamorelin was studied in registered, placebo-controlled trials with imaging endpoints; sermorelin has a long history as a diagnostic agent for pituitary function; CJC-1295 without DAC has comparatively sparse peer-reviewed pharmacokinetic literature and is frequently described using data borrowed from the DAC-bearing analogue.

What the published human data actually covers

Tesamorelin's trial programme reported changes in visceral adipose tissue measured by computed tomography, alongside IGF-1 and lipid measures, in a defined clinical population. Sermorelin appears in endocrine literature primarily as a provocative test of somatotroph reserve. Ipamorelin's peer-reviewed human record is limited to early-phase and postoperative ileus studies, which did not proceed to approval. For CJC-1295 without DAC, the human literature is thin enough that any claim about downstream outcomes should be treated as unestablished rather than merely uncertain.

A practical reading rule: when the four are presented as interchangeable, the presentation is not derived from the literature. Depth of evidence, not potency, is what separates them.

Reading each compound's page

Each compound has its own research library entry with sequence and identifier tables, separated in-vitro, animal and human evidence, a study table with citations, and an explicit limitations section. Those pages are the reference; this article is only the map that connects them.

Related research

References

  1. Falutz, J., et al. (2010). Effects of tesamorelin on visceral adipose tissue in HIV-infected patients with abdominal fat accumulation. Journal of Acquired Immune Deficiency Syndromes. View source
  2. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. View source
  3. Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. View source
  4. Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GHRH. Journal of Clinical Endocrinology & Metabolism. View source

Frequently asked questions

In the research literature, the term covers compounds that stimulate growth-hormone release from the pituitary through one of two main routes: agonism of the ghrelin/GHS receptor (GHSR) or agonism of the GHRH receptor. The route matters because receptor pharmacology, pulsatility and downstream markers differ between the two classes.

Ipamorelin is a selective GHSR agonist studied for stimulating pulsatile growth-hormone release, while CJC-1295 is a GHRH analogue engineered for extended activity. They act on different receptors, so their study designs, endpoints and pharmacokinetic considerations are not interchangeable — a key point when comparing published results across the two.

Because the outcome literature for these compounds is predominantly preclinical and heterogeneous, while the receptor pharmacology is comparatively well defined. Comparing mechanisms gives laboratories a firmer basis for designing experiments than comparing outcome claims drawn from dissimilar animal models. None of these materials is supplied for human use.